News Briefing channel feed – Endpoints News

News Briefing channel feed

Fate raises $57M; Biogen vet named CSO at Scholar Rock

9 years ago

Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug

9 years ago

Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash

9 years ago

Another South San Francisco biotech campus takes shape; WSJ: Feds plan charges in Valeant kickback scheme

9 years ago

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

9 years ago

Low-profile BeyondSpring files for $100M IPO to back cancer work; Erytech hammered after it pulls marketing application

9 years ago

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

9 years ago

Bristol-Myers partners with Johns Hopkins on Opdivo pact; A Valeant by any other name…

9 years ago

Adaptimmune surges after FDA lifts partial hold; Anthera tanks on PhIII flop; Kadmon axes staffers in restructuring

9 years ago

Bristol-Myer's Opdivo teams up with Infinity's last hope

9 years ago

Stanford team preps first human CRISPR study for sickle cell disease cure; Shkreli fingers his former attorneys

9 years ago

Therapix Bio in the hunt for $12M micro IPO; Progenics bags $50M loan; Juno isn't going anywhere, for now

9 years ago

Alnylam spells out just why it scrapped revusiran following patient deaths; Innocoll shares plunge on PhIII flops

9 years ago

SEC subpoenaes BioMarin in drisapersen probe; Job hunting? The FDA has hundreds of open positions

9 years ago

CRISPR upstart Casebia picks Sanofi vet Burns as new CEO; On the heels of a trial debacle, Opexa sheds staffers

9 years ago

Bon appetit: Cellectis CEO Choulika hosts a gene-edited feast; CRO Medpace adding 650 staffers

9 years ago

What’s on Sanofi’s M&A list now that Medivation is gone? Catalyst gets an SPA; Adaptimmune partners with Merck

9 years ago

Prominent MIT scientist Susan Lindquist dies of cancer; Election fears damaging biotech stocks?; Promethera adds 10M euros in VC cash

9 years ago

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

9 years ago

GV backs new genomics R&D upstart; Vertex advances plans for next-gen CF drugs

9 years ago

The clock is ticking on Eli Lilly’s big Alzheimer’s gamble; Pluristem reaches terms on $30M investment from China group

9 years ago

China: Fraud not the only reason 1,193 drug applications were withdrawn; Advaxis shares drop

9 years ago

Porges to Biogen: I don’t like your neuropathic pain drug; Ex-Moderna exec Bolen joins PureTech as CSO

9 years ago

Investors add $17M to Emulate Series B as Covance partners; UMass professor to work with Spark on next-gen vectors

9 years ago

First page Previous page 74 75 767778 79 80 Next page Last page